GeneDx is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Learn ...

New innovations designed to simplify NGS workflows Enhances critical variant identification through improved ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.

Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...

Moby summary of GeneDx Holdings Corp.'s Q4 2025 earnings call ...

Well, a global leader in NGS library construction technology, today announced the launch of MosaiX, a next-generation library prep kit designed to streamline a wide range of high-throughput ...

New @hopkinskimmel research finds extra copies of chromosome 1q may drive the earliest stages of pancreatic cancer. › ...

GeneMetrics was established by a group of clinicians, scientists, and legal experts committed to addressing a fragmented ...

In India, rare diseases are not so rare. It is estimated that around 70 million Indians live with one of more than 7,000 rare diseases, many of which are genetic […] ...

A 10-year study shows that a multipronged approach using whole exome sequencing can improve diagnostic yield in patients with ...

GeneDx Holdings: recent performance and business profile GeneDx Holdings (WGS) has been on many investors’ radars after recent price moves, with the stock showing a 1 day return of about 1% and month ...

Pacific Biosciences of California, Inc. ( PACB) Q4 2025 Earnings Call February 12, 2026 5:00 PM EST Good day, and welcome to PacBio's Fourth Quarter and Full Year 2025 Earnings Conference Call. Please ...